Entero Therapeutics, Inc. (ENTO )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ENTO
- Company Entero Therapeutics, Inc.
- Price $0.63
- Changes Percentage 1.88
- Change 0.0116
- Day Low $0.57
- Day High $0.65
- Year High $14.51
- Year Low $0.19
- Market Cap $2,995,039
- Price Avg 50 EMA (D) $0.58
- Price Avg 200 EMA (D) $1.62
- Exchange NASDAQ
- Volume 64,853
- Average Volume 470,222
- Open $0.6
- Previous Close $0.62
- EPS 14.17
- PE 0.04
- Earnings Announcement 2025-02-26 12:00:00
- Shares Outstanding $4,754,030
Company brief: ENTERO THERAPEUTICS, INC. (ENTO )
- Healthcare
- Biotechnology
- Mr. James R. Sapirstein M.B.A., R.Ph.
- https://www.firstwavebio.com
- US
- N/A
- 10-11-2016
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.